Cargando…

Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis

Cardiac amyloidosis (CA) is an infiltrative disease caused by progressive deposition of amyloid fibres in the heart. The most common forms include immunoglobulin light-chain and transthyretin amyloidosis. Current therapies for CA either stabilize or block the production of amyloidogenic precursors,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emdin, Michele, Morfino, Paolo, Crosta, Lucia, Aimo, Alberto, Vergaro, Giuseppe, Castiglione, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	CCC 2023 - State of the Art Cardiology Supplement Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120953/ https://www.ncbi.nlm.nih.gov/pubmed/37091656 http://dx.doi.org/10.1093/eurheartjsupp/suad079

Ejemplares similares

Treatment of amyloidosis: present and future
por: Mallus, Maria Teresa, et al.
Publicado: (2023)

Therapy of Type 2 diabetes: more gliflozines and less metformin?
por: Verdecchia, Paolo, et al.
Publicado: (2023)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

The treatment of amyloidosis is being refined
por: Cantone, Anna, et al.
Publicado: (2022)

Indications, evidence, and controversy in the closure of the left atrial appendage
por: Patti, Giuseppe, et al.
Publicado: (2023)

Acute coronary syndromes: hospital management of dyslipidaemia with proprotein convertase subtilisin/kexin 9 inhibitors: time to act
por: Musumeci, Giuseppe, et al.
Publicado: (2023)

Ablation of ventricular arrhythmias in cardiogenetic diseases
por: Pappone, Carlo, et al.
Publicado: (2023)

What is the role of coronary revascularization to recover the contractility of the dysfunctional heart?
por: Vassiliki’ Cousoumbas, Gloria, et al.
Publicado: (2023)

Heart failure therapy: the fifth card
por: Balestrieri, Giulio, et al.
Publicado: (2023)

Cardiovascular toxicity from therapies for light chain amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2023)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
por: Morfino, Paolo, et al.
Publicado: (2022)

Nightmare in the ward: difficult Clostridioides infection
por: Tarasi, Agapito
Publicado: (2023)

Takotsubo syndrome: more frequent in women, more dangerous in men
por: Natale, Enrico, et al.
Publicado: (2023)

Arrhythmic risk stratification in non-ischaemic dilated cardiomyopathy
por: Del Mestre, Eva, et al.
Publicado: (2023)

The temptation of anticoagulant therapy after transcatheter aortic valve implantation
por: Gatto, Laura, et al.
Publicado: (2023)

Atrial fibrillation in heart failure: drugs or ablation?
por: Palmas, Francesco, et al.
Publicado: (2023)

Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect?
por: Bisceglia, Irma, et al.
Publicado: (2023)

Sudden death in ischemic heart disease: looking for new predictors: polygenic risk
por: Boccanelli, Alessandro, et al.
Publicado: (2023)

The metaverse in medicine
por: Massetti, Massimo, et al.
Publicado: (2023)

How much does the presentation pattern of atrial fibrillation affect thrombo-embolic risk and mortality?
por: Turturiello, Dario, et al.
Publicado: (2023)

Treatment of multiple valve disease: surgery, structural intervention, or both?
por: Berti, Sergio, et al.
Publicado: (2023)

Sudden cardiac death in ischaemic heart disease: coronary thrombosis or myocardial fibrosis?
por: Prati, Francesco, et al.
Publicado: (2023)

Old and new therapeutic solutions in the treatment of hypertrophic cardiomyopathy
por: Autore, Camillo, et al.
Publicado: (2023)

Treating chronic kidney disease to reduce cardiovascular risk
por: Cice, Gennaro, et al.
Publicado: (2023)

The new in anticoagulation: factor XI inhibitors
por: Muscente, Francesca, et al.
Publicado: (2023)

In search of new gatekeepers: coronary CT (Computed Tomography) in acute coronary syndrome
por: Schillaci, Matteo, et al.
Publicado: (2023)

Causes of sudden death
por: De Gaspari, Monica, et al.
Publicado: (2023)

Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
por: Ferri, Nicola, et al.
Publicado: (2023)

Long-term follow-up after invasive or conservative management of stable coronary disease: the ISCHEMIA-EXTEND study
por: Bolognese, Leonardo, et al.
Publicado: (2023)

A focus on the percutaneous therapy of mitral and tricuspid regurgitation
por: Frazzetto, Marco, et al.
Publicado: (2023)

DOACs and rheumatic valvulopathy: always a red light?
por: Rochira, Carla, et al.
Publicado: (2023)

Challenges in cardiology: diagnosis of native and prosthetic valve endocarditis
por: Pepi, Mauro, et al.
Publicado: (2023)

Renal denervation and long-term results
por: Simonetti, Fiorenzo, et al.
Publicado: (2023)

Spontaneous coronary artery dissection: an unpredictable event
por: Smirnova, Alexandra, et al.
Publicado: (2023)

Less sodium and more potassium to reduce cardiovascular risk
por: Muiesan, Maria Lorenza, et al.
Publicado: (2023)

Progress in the treatment of acute pulmonary embolism and chronic thrombo-embolic pulmonary hypertension/disease
por: Palazzini, Massimiliano, et al.
Publicado: (2023)

Impact of the exposome on cardiovascular disease
por: Bonanni, Alice, et al.
Publicado: (2023)

Predicting left ventricular functional recovery in ischaemic cardiomyopathy: needs and challenges
por: Radesich, Cinzia, et al.
Publicado: (2023)

Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023)

Dilemmas in cardiology: when to recanalize a chronic total occlusion
por: Stazi, Filippo
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_326dm0d329i0ngt8bkcg3edvo0